Last reviewed · How we verify
Chemotherapeutic Agent
Chemotherapeutic Agent is a Small molecule drug developed by Fudan University. It is currently FDA-approved. Also known as: COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin.
Avelumab is a small molecule chemotherapeutic agent used to treat various types of cancer, including unresectable, locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, and metastatic non-small cell lung cancer. It is classified as an active alkylating agent, which is a type of chemotherapeutic agent that works by interfering with DNA replication.
At a glance
| Generic name | Chemotherapeutic Agent |
|---|---|
| Also known as | COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin |
| Sponsor | Fudan University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (PHASE3)
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (PHASE1)
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (PHASE1)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors (PHASE1, PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapeutic Agent CI brief — competitive landscape report
- Chemotherapeutic Agent updates RSS · CI watch RSS
- Fudan University portfolio CI
Frequently asked questions about Chemotherapeutic Agent
What is Chemotherapeutic Agent?
Who makes Chemotherapeutic Agent?
Is Chemotherapeutic Agent also known as anything else?
What development phase is Chemotherapeutic Agent in?
Related
- Manufacturer: Fudan University — full pipeline
- Also known as: COG-V/C, SIOPe-LGG-V/C, VBL, Carboplatin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing